VYEPTI

This brand name is authorized in Austria, Estonia, Spain, France, Israel, Lithuania, Poland, Romania, United States

Active ingredients

The drug VYEPTI contains one active pharmaceutical ingredient (API):

1 Eptinezumab UNII 8202AY8I7H - EPTINEZUMAB

Eptinezumab is a recombinant humanized immunoglobulin G1 (IgG1) antibody that binds to α- and β-forms of human calcitonin gene-related peptide (CGRP) ligand with low picomolar affinity. Eptinezumab prevents the activation of the CGRP receptors and hence the downstream cascade of physiological events linked to initiation of migraine attacks. Read about Eptinezumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VYEPTI Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR
VYEPTI Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N02CD05		N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CD Calcitonin gene-related peptide (CGRP) antagonists
Discover more medicines within N02CD05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1874358
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1211599001
Country: FR	Base de données publique des médicaments	Identifier(s): 64842858
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9347
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1094046, 1096010
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100465456
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69462001, W69462002
Country: US	FDA, National Drug Code	Identifier(s): 67386-130